MoonLake Immunotherapeutics(MLTX)Earnings, Financials & Key Ratios

This clinical-stage biotech focused on Nanobody therapies reported a notable insider sale.

MoonLake Immunotherapeutics maintains a Buy rating, supported by positive FDA interactions and strong long-term data for sonelokimab in hidradenitis suppurativa [HS]. MLTX expects to submit a BLA for sonelokimab in HS by end of September 2026, targeting both adults and adolescents, with possible acceptance for review by November 2026. 52-week VELA data show 67.2% HiSCR75 response, positioning sonelokimab as a potential best-in-class therapy and supporting a broad label proposal thanks to VELA-TEEN adolescent study.

It aims to raise up to $200 million in the offering. This will support its efforts to bring its top drug candidate to market.

ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced the pricing of an underwritten public offering of 9,000,000 Class A ordinary shares at a public offering price per share of $20.00 and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase up to 1,000,000 Class A ordinary shares at a public offering price per pre-funded warrant of $19.9999, which equals the public offering price per Class A ordinary share less the $0.0001 per share exercise price of each pre-funded warrant. The pre-funded warrants are exercisable immediately. The gross proceeds from the offering to MoonLake, before deducting the underwriting discounts and commissions and other offering expenses payable by MoonLake, are expected to be approximately $200 million. In addition, MoonLake has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,500,000 Class A ordinary shares at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about June 25, 2026 subject to the satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by MoonLake.

MoonLake Immunotherapeutics is positioned for upside on differentiated efficacy and a large, underpenetrated hidradenitis suppurativa, or HS, market. Recent Phase 3 VELA data show sonelokimab achieves superior HiSCR75/100 response rates and meaningful patient-reported quality of life improvements. The commercial strategy targets a best-in-class FDA label by emphasizing efficacy, safety, and patient outcomes, supporting share gains in a $10–15B market.